|Other Names||Mitogen-activated protein kinase kinase kinase 4, MAP three kinase 1, MAPK/ERK kinase kinase 4, MEK kinase 4, MEKK 4, MAP3K4, KIAA0213, MAPKKK4, MEKK4, MTK1|
|Target/Specificity||The synthetic peptide sequence used to generate the antibody AP1917a was selected from the N-term region of human MAPK34. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.|
|Format||The synthetic peptide was lyophilized with 100% acetonitrile and is supplied as a powder. Reconstitute with 0.1 ml deionized water for a final concentration of 1 mg/ml.|
|Storage||Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.|
|Precautions||This product is for research use only. Not for use in diagnostic or therapeutic procedures.|
|Synonyms||KIAA0213, MAPKKK4, MEKK4, MTK1|
|Function||Component of a protein kinase signal transduction cascade. Activates the CSBP2, P38 and JNK MAPK pathways, but not the ERK pathway. Specifically phosphorylates and activates MAP2K4 and MAP2K6.|
|Cellular Location||Cytoplasm, perinuclear region. Note=Localized in perinuclear vesicular-like structures, probably Golgi-associated vesicles.|
|Tissue Location||Expressed at high levels in heart, placenta, skeletal muscle and pancreas, and at lower levels in other tissues.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
The central core of each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of 3 protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which then activates a specific MAPK. While the ERK MAPKs are activated by mitogenic stimulation, the CSBP2 and JNK MAPKs are activated by environmental stresses such as osmotic shock, UV irradiation, wound stress, and inflammatory factors. MAPK34 is a MAPKKK, and contains a protein kinase catalytic domain at the C terminus. The N-terminal nonkinase domain may contain a regulatory domain. Expression of MAPK34 in mammalian cells activates the CSBP2 and JNK MAPK pathways, but not the ERK pathway. In vitro kinase studies indicate that recombinant MAPK34 can specifically phosphorylate and activate PRKMK6 and SERK1, MAPKKs that activate CSBP2 and JNK, respectively but cannot phosphorylate PRKMK1, an MAPKK that activates ERKs. MAPK34 is a major mediator of environmental stresses that activate the CSBP2 MAPK pathway, and a minor mediator of the JNK pathway.
Luo, W., et al., J. Biol. Chem. 278(39):37451-37458 (2003).Kovalsky, O., et al., J. Biol. Chem. 276(42):39330-39339 (2001).Posas, F., et al., EMBO J. 17(5):1385-1394 (1998).Takekawa, M., et al., Cell 95(4):521-530 (1998).Gerwins, P., et al., J. Biol. Chem. 272(13):8288-8295 (1997).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.